Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain activ... Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. 더 보기
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0134 | 2.53308128544 | 0.529 | 0.619 | 0.49 | 146620 | 0.56041482 | CS |
4 | -0.0021 | -0.385674931129 | 0.5445 | 0.7999 | 0.44 | 362103 | 0.56769869 | CS |
12 | 0.0064 | 1.19402985075 | 0.536 | 1.09 | 0.44 | 285224 | 0.64146272 | CS |
26 | -0.2656 | -32.8712871287 | 0.808 | 1.1099 | 0.44 | 242826 | 0.74693661 | CS |
52 | -0.3177 | -36.9375653994 | 0.8601 | 1.87 | 0.44 | 130377 | 0.77472074 | CS |
156 | -5.2576 | -90.6482758621 | 5.8 | 5.88 | 0.44 | 63981 | 1.50913761 | CS |
260 | -14.4176 | -96.3743315508 | 14.96 | 19.56 | 0.44 | 343532 | 10.35193504 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관